Type your tag names separated by a space and hit enter

Urinary metabolites of histamine and leukotrienes before and after placebo-controlled challenge with ASA and food additives in chronic urticaria patients.

Abstract

BACKGROUND

The recovery of mediator metabolites from urine has the potential to provide a rapid, safe, and easily available index of release of mediators. We aimed to determine urinary metabolites of both histamine and leukotrienes (LTs) in patients affected by chronic urticaria (CU).

METHODS

Twenty patients with CU were studied. They were selected on the basis of double-blind placebo-controlled challenge (DBPC) with acetyl salicylic acid (ASA) and food additives. Ten patients (group B) were negative to both challenges. Ten patients (group C) presented urticaria and/or the appearance of angioedema during or 24 h after challenge, with reactions to ASA (five patients) or food additives (five patients). We recruited 15 healthy volunteers as controls (group A). During a second challenge, groups B and C were challenged double-blind with a single dose of ASA, or a specific food additive, or placebo. The healthy group was challenged only with a placebo (talc capsule). Patients in groups B and C were challenged twice: with placebo (as groups B1 and C1) and with ASA (groups B2 and C2) or food additives (C2). Four samples of urine were collected; one during the night before the specific or sham challenge (baseline), and three at 2, 6 and 24 h after the challenge. Urinary methylhistamine (N-MH) and LTE4 were analyzed and normalized for urinary creatinine.

RESULTS

For urinary N-MH at baseline, there was a significant difference only between group A and groups B1, B2, C1 and C2 (A vs. B1, P < 0.0001; A vs. B2, P < 0.0001; A vs. C1, P < 0.0001; A vs. C2, P < 0.0001). We detected a significant variation in urinary methylhistamine excretion only in group C2 after 2 h, 6 h and 24 h (P < 0.0001). However, no variations were observed in N-MH excretion rate in the other groups (A, B1, C1) after challenge with placebo, and in B2 after challenge with ASA 20 mg. For urinary LTE4 at baseline no differences were found between the mean values for the different groups. After specific challenge, only C2 patients showed significantly increased excretion rates of urinary LTE4 compared with the other groups challenged with placebo (A, B1, C1), or ASA (B2) (P < 0.0001). No significant correlation was seen between urinary LTE4 and methylhistamine excretion rate in any patients.

CONCLUSION

Our results show that urinary excretion of N-MH and LTE4 is different for CU patients without ASA or food hypersensitivity, compared to those with CU with ASA or food additive hypersensitivity after specific challenge.

Links

  • FREE Publisher Full Text
  • Authors+Show Affiliations

    ,

    Dipartimento di Medicina Clinica e delle Patologie Emergenti, Università degli Studi di Palermo, Italy.

    , , , , , ,

    Source

    Allergy 57:12 2002 Dec pg 1180-6

    MeSH

    Administration, Oral
    Adult
    Aspirin
    Biomarkers
    Bronchoconstrictor Agents
    Chronic Disease
    Controlled Clinical Trials as Topic
    Cyclooxygenase Inhibitors
    Dose-Response Relationship, Drug
    Double-Blind Method
    Drug Hypersensitivity
    Female
    Food Additives
    Humans
    Italy
    Leukotriene E4
    Male
    Methylhistamines
    Middle Aged
    Sodium Benzoate
    Sodium Glutamate
    Sulfites
    Tartrazine
    Time Factors
    Urticaria

    Pub Type(s)

    Comparative Study
    Journal Article
    Research Support, Non-U.S. Gov't

    Language

    eng

    PubMed ID

    12464047

    Citation

    Di Lorenzo, G, et al. "Urinary Metabolites of Histamine and Leukotrienes Before and After Placebo-controlled Challenge With ASA and Food Additives in Chronic Urticaria Patients." Allergy, vol. 57, no. 12, 2002, pp. 1180-6.
    Di Lorenzo G, Pacor ML, Vignola AM, et al. Urinary metabolites of histamine and leukotrienes before and after placebo-controlled challenge with ASA and food additives in chronic urticaria patients. Allergy. 2002;57(12):1180-6.
    Di Lorenzo, G., Pacor, M. L., Vignola, A. M., Profita, M., Esposito-Pellitteri, M., Biasi, D., ... Caruso, C. (2002). Urinary metabolites of histamine and leukotrienes before and after placebo-controlled challenge with ASA and food additives in chronic urticaria patients. Allergy, 57(12), pp. 1180-6.
    Di Lorenzo G, et al. Urinary Metabolites of Histamine and Leukotrienes Before and After Placebo-controlled Challenge With ASA and Food Additives in Chronic Urticaria Patients. Allergy. 2002;57(12):1180-6. PubMed PMID: 12464047.
    * Article titles in AMA citation format should be in sentence-case
    TY - JOUR T1 - Urinary metabolites of histamine and leukotrienes before and after placebo-controlled challenge with ASA and food additives in chronic urticaria patients. AU - Di Lorenzo,G, AU - Pacor,M L, AU - Vignola,A M, AU - Profita,M, AU - Esposito-Pellitteri,M, AU - Biasi,D, AU - Corrocher,R, AU - Caruso,C, PY - 2002/12/5/pubmed PY - 2003/4/17/medline PY - 2002/12/5/entrez SP - 1180 EP - 6 JF - Allergy JO - Allergy VL - 57 IS - 12 N2 - BACKGROUND: The recovery of mediator metabolites from urine has the potential to provide a rapid, safe, and easily available index of release of mediators. We aimed to determine urinary metabolites of both histamine and leukotrienes (LTs) in patients affected by chronic urticaria (CU). METHODS: Twenty patients with CU were studied. They were selected on the basis of double-blind placebo-controlled challenge (DBPC) with acetyl salicylic acid (ASA) and food additives. Ten patients (group B) were negative to both challenges. Ten patients (group C) presented urticaria and/or the appearance of angioedema during or 24 h after challenge, with reactions to ASA (five patients) or food additives (five patients). We recruited 15 healthy volunteers as controls (group A). During a second challenge, groups B and C were challenged double-blind with a single dose of ASA, or a specific food additive, or placebo. The healthy group was challenged only with a placebo (talc capsule). Patients in groups B and C were challenged twice: with placebo (as groups B1 and C1) and with ASA (groups B2 and C2) or food additives (C2). Four samples of urine were collected; one during the night before the specific or sham challenge (baseline), and three at 2, 6 and 24 h after the challenge. Urinary methylhistamine (N-MH) and LTE4 were analyzed and normalized for urinary creatinine. RESULTS: For urinary N-MH at baseline, there was a significant difference only between group A and groups B1, B2, C1 and C2 (A vs. B1, P < 0.0001; A vs. B2, P < 0.0001; A vs. C1, P < 0.0001; A vs. C2, P < 0.0001). We detected a significant variation in urinary methylhistamine excretion only in group C2 after 2 h, 6 h and 24 h (P < 0.0001). However, no variations were observed in N-MH excretion rate in the other groups (A, B1, C1) after challenge with placebo, and in B2 after challenge with ASA 20 mg. For urinary LTE4 at baseline no differences were found between the mean values for the different groups. After specific challenge, only C2 patients showed significantly increased excretion rates of urinary LTE4 compared with the other groups challenged with placebo (A, B1, C1), or ASA (B2) (P < 0.0001). No significant correlation was seen between urinary LTE4 and methylhistamine excretion rate in any patients. CONCLUSION: Our results show that urinary excretion of N-MH and LTE4 is different for CU patients without ASA or food hypersensitivity, compared to those with CU with ASA or food additive hypersensitivity after specific challenge. SN - 0105-4538 UR - https://www.unboundmedicine.com/medline/citation/12464047/full_citation L2 - https://onlinelibrary.wiley.com/resolve/openurl?genre=article&amp;sid=nlm:pubmed&amp;issn=0105-4538&amp;date=2002&amp;volume=57&amp;issue=12&amp;spage=1180 DB - PRIME DP - Unbound Medicine ER -